Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- UCBAxios Names UCB a Winner of the Metro Atlanta Top Workplaces 2026 AwardRecognition reflects employee feedback and comes as UCB expands its Georgia footprint through a $2 billion investment in a new biomanufacturing campus expected to create more than 330 jobs. — UCB, a global biopharmaceutical company with its U.S....
- CanSinoBIO's NDA for Td5cp Adolescent and Adult Accepted, Further Strengthening Its Diversified Vaccine PipelineOn August 16, 2026, CanSino Biologics Inc. ("CanSinoBIO"; HKEX: 06185/SHSE: 688185) announced that the New Drug Application (NDA) for its Tetanus, Reduced Diphtheria and Pertussis (Acellular, Five Components) Combined Vaccine, Adsorbed (for people aged six years and above; the "Td5cp Adolescent and Adult") has been formally accepted by China's National Medical Products Administration (NMPA). As a booster vaccine for adolescents and adults, the product was granted Priority Review status in May 2026. If approved and launched, it is expected to create synergies with the recently approved next-generation three-component DTaP vaccine Tripecia(R) (DT3cP Infant), further strengthening CanSinoBIO's pertussis-containing vaccine portfolio across different age groups. Pertussis is a highly contagious acute respiratory infectious disease caused by Bordetella pertussis¹. In recent years, the disease has experienced a global resurgence. Data show that reported pertussis cases in China exceeded 470,000 in 2024¹, representing an approximately 12-fold increase compared with 2023 and drawing sustained attention to disease prevention and control. Against this backdrop, in addition to primary immunization in infants, the importance of booster immunization during adolescence and adulthood has become increasingly evident. Vaccination with diphtheria, tetanus and pertussis-containing vaccines is an important measure for preventing the related diseases, yet China has long lacked a dedicated booster immunization product for people aged six years and above. In April this year, CanSinoBIO's Diphtheria, Tetanus and Pertussis (Acellular, Three Components) Combined Vaccine, Adsorbed for infants—Tripecia(R) (DT3cP Infant)—was approved for marketing through the NMPA's Priority Review pathway, marking an important breakthrough for the company in component-based pertussis vaccine technology. Compared with the three-component (PT, FHA and PRN) DT3cP vaccine, the Td5cp Adolescent and Adult includes two additional pertussis antigens, FIM2 and FIM3. Each pertussis antigen is individually purified and formulated at precise ratios, helping ensure stable product quality and batch-to-batch consistency. The continued advancement of this product will also support further exploration of innovative component-based pertussis vaccine technology across broader age groups. In July 2026, seven departments, including the National Disease Control and Prevention Administration and the National Development and Reform Commission, jointly issued the "15th Five-Year Plan for Disease Prevention and Control", which explicitly calls for the implementation of a life-course immunization strategy covering the entire population. As public health needs continue to evolve, providing more comprehensive immunization protection solutions for people at different stages of life has become an important direction for vaccine innovation. If the Td5cp Adolescent and Adult is successfully approved and launched, it will further enrich CanSinoBIO's pertussis-containing vaccine portfolio and support the company's continued efforts to strengthen its innovative vaccine portfolio across all age groups. From a capital market perspective, the acceptance of the NDA for the Td5cp Adolescent and Adult marks the product's formal entry into a key regulatory review stage. It also represents important progress in CanSinoBIO's continued advancement of innovative vaccine R&D and commercialization, while strengthening market expectations for the development of the company's pipeline of combination vaccine candidates and laying a solid foundation for the company's medium- to long-term performance growth. References: 1. Chinese Center for Disease Control and Prevention: https://www.chinacdc.cn/jkyj/mygh02/jbzt/xjxcrb/brk/202409/t20240925_300997.html 2. Zhang W, Wei C, Wan P, et al. Safety and immunogenicity of diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed after three-dose priming in 2 months age infants: a randomized, blinded, controlled phase III clinical trial in China. Emerg Microbes Infect. 2026 Feb;15(1):2625556. 3. Dai H, Sui X, Che J, et al. Pathogenicity and vaccine protection of circulating pertactin- and filamentous hemagglutinin-deficient Bordetella pertussis strains. Emerg Microbes Infect. 2026 Feb;15(1):2640283. 4. CSR data on file
- ThinkCareBelieve: Week 82 of the Trump 2.0 AdministrationNot only has DHS spent $20 Million on shock gloves for ICE Agents, but it turns out that Dr. Fauci knew that Covid Vaccines were causing miscarriages.
- NASDAQ: CAPR: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Capricor Therapeutics, IncDid you buy CAPR securities between December 17, 2025 and July 26, 2026?
- The Rosen Law Firm PAROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPRWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
- The Rosen Law Firm PAROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRYWHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 5, 2026.SO WHAT: If you purchased ARS Pharmaceuticals securities...
- Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the FirmKessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on behalf of investors who purchased or acquired Alnylam Pharmaceuticals, Inc. securities and experienced significant financial losses.
- Aizen TherapeuticsAizen Enters into Collaboration with San Diego Biopharma to Advance Oral BiologicsMulti-program deal with revenue potential of $100 million per target — Aizen Therapeutics, an AI-native biotechnology company focused on building oral biologics, today announced a multi-program collaboration with a San Diego-based, public biotech to...
- Kleiman / RajaramKleiman Rajaram and Phillips & Cohen Announce Successful $46 Million Qui Tam Action Against Veloxis PharmaceuticalsVeloxis Admits to Kickbacks, and to Pay Criminal Fines and Civil Penalties — In a major healthcare fraud enforcement action, Veloxis Pharmaceuticals will pay over million and accept a stringent deferred prosecution agreement after admitting illegal...
- Kahn Swick & Foti, LLCCapricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineKahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NasdaqGS: CAPR) of a class action securities...
- Citizens Commission on Human Rights International Los AngelesCitizens Commission on Human Rights International Releases White Paper on Antidepressants and Psychiatric Drug ReformFederal deprescribing push and Florida’s new guidance underscore CCHR’s decades-long call to prevent misdiagnosis, harmful drugs, and needless suffering.
- Actinium Pharmaceuticals, Inc.Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing UpdateActinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents adding to a broad...